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ARTICLE

Defining the genotypic and phenotypic spectrum of X-linked
MSL3-related disorder
A full list of authors and affiliations appears at the end of the paper.
Purpose: We sought to delineate the genotypic and phenotypic
spectrum of female and male individuals with X-linked, MSL3related disorder (Basilicata–Akhtar syndrome).
Methods: Twenty-five individuals (15 males, 10 females) with
causative variants in MSL3 were ascertained through exome or
genome sequencing at ten different sequencing centers.
Results: We identified multiple variant types in MSL3 (ten
nonsense, six frameshift, four splice site, three missense, one inframe-deletion, one multi-exon deletion), most proven to be de
novo, and clustering in the terminal eight exons suggesting that
truncating variants in the first five exons might be compensated by
an alternative MSL3 transcript. Three-dimensional modeling of
missense and splice variants indicated that these have a deleterious
effect. The main clinical findings comprised developmental delay
and intellectual disability ranging from mild to severe. Autism
spectrum disorder, muscle tone abnormalities, and macrocephaly

INTRODUCTION
MSL3 resides on the X-chromosome and encodes a subunit of
the chromatin-associated male specific lethal (MSL) complex.1,2
The MSL complex mediates global histone H4 lysine-16
acetylation (H4K16ac) and plays a crucial role as an epigenetic
modulator in flies and mammals.1–4 In mammalian species, the
core MSL complex consists of MSL1, MSL2, MSL3, and MOF
(males absent on the first).2,3,5 MSL3 itself contains a C-terminal
morf-related gene (MRG) domain, responsible for MSL
complex formation, and an N-terminal chromo domain (CD),
implicated in chromatin targeting.6–12
MSL3 was first identified as a candidate gene in the
Deciphering Developmental Disorder Study13 and was recently
described as the underlying genetic cause of Basilicata–Akhtar
syndrome (MIM 301032), a novel X-linked neurodevelopmental disorder that equally affects female and male individuals.14 In
a total of 16 patients (including two siblings), exome sequencing
revealed a variety of associated variant types in MSL3, but
mainly loss-of-function variants. Except for the siblings with
suspected parental mosaicism and a maternally inherited Xchromosome inversion, all variants occurred de novo. In
transfected HEK293 cells, mutant proteins displayed loss of
interaction with the histone acetyltransferase MOF and with

were common as well as hearing impairment and gastrointestinal
problems. Hypoplasia of the cerebellar vermis emerged as a
consistent magnetic resonance image (MRI) finding. Females and
males were equally affected. Using facial analysis technology, a
recognizable facial gestalt was determined.
Conclusion: Our aggregated data illustrate the genotypic and
phenotypic spectrum of X-linked, MSL3-related disorder
(Basilicata–Akhtar syndrome). Our cohort improves the understanding of disease related morbidity and allows us to propose
detailed surveillance guidelines for affected individuals.
Genetics in Medicine (2021) 23:384–395; https://doi.org/10.1038/s41436020-00993-y
Keywords: autism; developmental delay; histone acetylation;
MSL3; X-linked

MSL1. In patient-derived cells, a bulk reduction of acetylated
H4K16 compared with wild type was observed. Transcriptome
analyses of patient cells showed dysregulation, mainly downregulation, of genes involved in developmental pathways.
Treatment with a histone deacetylase inhibitor in vitro restored
acetylation levels and MSL3 mutant cells adopted the migratory
behavior of the control cells.
Common clinical features in affected individuals include
global developmental delay, delayed speech, muscular hypotonia, feeding difficulties in early infancy, progressive
spasticity, and overlapping facial dysmorphism.14
However, with only 16 individuals described to date, the full
genotypic and phenotypic spectrum of MSL3-related syndrome remains incompletely elucidated. Hence, this study
aims to provide a comprehensive clinical and molecular
characterization of individuals with causative variants in
MSL3, to study possible genotype–phenotype correlations and
to determine sex-specific differences.

MATERIALS AND METHODS
Participants and samples

Individuals with disease associated variants in MSL3 were
ascertained via the public data sharing platform GeneMatcher
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(entry “MSL3”)15 and via a Facebook family group
(“MSL3 syndrome”). All individuals or their legal guardians
gave written informed consent for their participation in the
study and the publication of detailed clinical data. Additional
informed consent was obtained when identifying images were
included in this article. We obtained and thoroughly reviewed
clinical records and genetic findings in every individual as
well as photographs and brain magnetic resonance images
(MRIs) when available. Individual 13 was previously published by Basilicata et al. (as P4)14 and was enrolled in this
study after obtaining additional clinical follow-up data.
Ethics statement

1234567890():,;

The study was performed in agreement with the ethical
standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki, and was approved by the local ethics
committee of the Technical University Munich (#5360/12S).

patterns. Twelve frontal facial photographs (P1, P2, P3, P5,
P6, P7, P8, P9, P10, P11, P12, P13) were obtained from
Basilicata et al.14 Individuals P14 and P15 were excluded as
deletions spanning more genes than MSL3 were identified in
the latter. For individual P4, who was also included in this
study (as individual 13), a more recent photograph was
chosen. Frontal images of additional 17 unpublished individuals from this study were available, thus adding up to a total
of 30 individuals applicable for facial analysis. Age-, sex-, and
ethnicity-matched controls were used as a comparison cohort.
As previously reported, a composite image of the affected
individuals was generated using the DeepGestalt facial
analysis and binary comparison between controls and affected
individuals was evaluated by measuring the receiver operating
characteristic (ROC) curves and the corresponding area under
the curve (AUC).22

RESULTS
Demographic features

Exome sequencing

Exome sequencing (ES), genome sequencing (GS), and MSL3
Sanger sequencing was carried out independently at ten
different research or diagnostic centers using genomic DNA
extracted from leukocytes or whole blood. Technical details
can be found in Supplementary Information. Variants’
pathogenicity was classified according to the American
College of Medical Genetics (ACMG) guidelines.16 Nonsense,
frameshift, and splice variants as well as multi-exon deletions
were classified as loss-of-function variants in contrast to
missense and indel variants.

Our cohort of 25 individuals with hemizygous or heterozygous variants in MSL3 includes 15 males and 10 females
whose ages ranged from 14 months to 30 years (median: 7.25
years, interquartile range: 3.08–16.33 years) at the time of the
last follow-up. Table 1 gives an overview of the clinical
phenotype of the 25 individuals described in this study.
Figure 1a displays the facial appearance of the individuals for
whom facial pictures were available. A comprehensive
summary of the clinical features of the 25 individuals is
provided in Table S1.
Neurological findings

Statistics

Statistical analyses were performed in R (version 3.5.3).17
Comparative analyses between females and males and
between loss-of-function variants and missense variants/inframe deletions were calculated using the Fisher’s exact test.18
Given the exploratory design of our study, P values < 0.05
were considered statistically significant. Counts for clinical
features are given only for those where the respective
information was available, therefore the total count can be
lower than the total number of individuals.
Molecular modeling

SpliceAI (Illumina) was used to predict splice junctions for
splice variants.19 For 3D modeling of identified missense
variants and splice variants that are predicted to escape
nonsense-mediated decay (NMD), we used the experimentally
solved structure of the MSL3:MSL1 tetramer complex (PDB:
2y0n)12 with unresolved loops modeled using homologybased methods.20 Variants were mapped to the protein
structure using custom scripts. ΔΔGfold was calculated for
each variant studied using FoldX version 4.0.21
Facial analysis

The DeepGestalt technology by Face2Gene (FDNA Inc.,
Boston, MA) was used to assess the presence of distinct facial
GENETICS in MEDICINE | Volume 23 | Number 2 | February 2021

Neurological abnormalities constituted the main clinical
phenotype of MSL3-related disorder. Developmental delay
(DD) was prominent in all individuals (n = 25/25, 100%),
with global DD in 24/25 (96%) individuals and isolated
speech development delay in 1/25 (4%) individual. Fifteen
of 16 (94%) individuals were diagnosed with intellectual
disability (ID). ID was classified as mild in 5/15 (33%)
individuals, moderate in 3/15 (20%) individuals, severe in
1/15 (7%) individuals, profound in 1/15 (7%) individuals,
and borderline intellectual functioning in 1/15 (7%)
individuals. Four of 15 (27%) individuals had received
the diagnosis of ID; however, the level of ID had not been
determined.
Twenty-two of 25 (88%) individuals had a history of
abnormal muscle tone, comprising truncal muscular hypotonia (n = 21) and/or spasticity of the upper and lower limbs (n
= 7) while 5 individuals had mixed tone. Muscular hypotonia
was predominantly evident in infancy, while spasticity
appeared to evolve with increasing age.
A heterogeneous spectrum of movement disorders was
reported including dystonia (n = 5/25; 20%), brady-/hypokinesia (n = 6/24; 25%), and ataxia (n = 6/23; 26%). Dystonic
movements were described as generalized as well as focal.
Three individuals had received the clinical diagnosis of
cerebral palsy before genetic testing was initialized.
385

386

1

Volume 23 | Number 2 | February 2021
−

NA

Brady-/hypokinesia (+/−)

−

−
NA
+
+
+
NA

+
+
+
+
severe
+
+
+
+
−
+

+
+
+
+
mild

+
+
+
NA
NA

4

+

−

−

−

−

−

−

NA
−

−
−
+
+
−
+
−

+
+
+
+
NA

−

−
−
−
+
−
−

+
+
+
+
mild

p.
(Arg458Leu)
hemizygous
de novo

c.1373G>T

19y 8m
male

18

heterozygous
de novo

c.5894_591del
p.?

female

5y 5m

p.
(Gln321*)
hemizygous
de novo

c.961C>T

19y 6m
male

17

+
+
+
−
−
+

hemizygous
de novo

hemizygous
de novo

Zygosity
Inheritance
Development
DD (+/−)
Speech delay (+/−)
Motor delay (+/−)
ID (+/−)
Level of intellectual
disability
Neurological findings
ASD (+/−)
Seizures (+/−)
Hypotonia (+/−)
Spasticity (+/−)
Dystonia (+/−)
Ataxia (+/−)

c.1171
+2_1171+4del
p.?

c.1362_1364del

p.(Gln454del)

Amino acid change

9y 1m
male

Age at last assessment
Gender
Variant (NM_078629.4)
cDNA change

7y 10m
male

+

15

+

+

−

+

−

−

+

−

−
−

−
+
+
−
−
−
−

Individual

+

−

−

+

−

+

−

−

−

+

+

−
−

−
−

−

−
NA
+
−
+
−
−

16

p.
(Asn437Thr)
heterozygous
de novo

p.
(Lys383Serfs*22)
heterozygous
de novo
+
+
+
+
mild

c.1310A>C

c.1146del

+
+
+
+
NA

female

female

3
4y 1m

1y 10m

2

−
−
+
−
−
−
+

+
+
+
NA
NA

Development
DD (+/−)
Speech delay (+/−)
Motor delay (+/−)
ID (+/−)
Level of intellectual
disability

Neurological findings
ASD (+/−)
Seizures (+/−)
Hypotonia (+/−)
Spasticity (+/−)
Dystonia (+/−)
Ataxia (+/−)
Brady-/
hypokinesia (+/−)
Additional findings
Macrocephaly (+/−)
Cardiovascular
abnormalites (+/−)
Respiratory
symptoms (+/−)
Gastrointestinal
disorder (+/−)
Disorder of the visual
system (+/−)
Hearing
abnormalities (+/−)
Skeletal features (+/
−)
Urinary
symptoms (+/−)
Brain MRI
abnormalities

heterozygous
de novo

Zygosity
Inheritance

Age at last
14m
assessment
Gender
female
Variant (NM_078629.4)
cDNA change
c.1466
+1G>A
Amino acid change
p.?

Individual

−

−

+

+

+

+

+

−
−

+
−
+
+
+
+
−

+
+
+
NA
NA

−

NA
−
+
NA
+
+

+
+
+
+
moderate

hemizygous
de novo

p.(Tyr438*)

c.1314C>A

23y
male

19

p.
(Gly441Argfs*2)
heterozygous
de novo

c.1319dup

female

5y 7m

5

+

NA
−
+
NA
−
−

+
+
+
+
moderate (to
severe)

hemizygous
NA

p.(Leu197*)

c.590_593del

30y
male

20

NA

NA

+

+

−

+

NA

−
+

NA
−
−
−
+
−
+

+
+
+
NA
NA

p.
(Pro270Valfs*8)
heterozygous
NA

c.808_809del

female

8y 1m

6

−

−
−
+
−
−
−

+
+
+
+
mild

hemizygous
de novo

p.(Lys289*)

c.865A>T

9y 10m
male

21

−

−

+

−

−

+

−

−
−

+
+
−
−
−
−
−

+
+
+
+
profound

heterozygous
de novo

−

−

+

−

+

−

−

+
−

+
−
+
+
−
−
+

−

NA
−
+
−
−
−

+
+
+
NA
NA

hemizygous
de novo

p.(Tyr449*)

+

−
−
+
+
−
−

+
+
+
−
NA

heterozygous
de novo

p.(Tyr189*)

c.566dup

9y 9m
female

23

+
+
−
+
moderate

p.
(Lys390Glufs*6)
heterozygous
not present
in mother

c.1168_1169del

female

17y 8m

8

c.1347C>A

15m
male

22

c.(465+1_466-1)_
(908+1_909-1)
p.?

female

16y 4m

7

+

−

+

−

+

+

−

+
−

−
−
+
−
−
−
−

−

+

+

−

+

+

+

+
−

+
−
+
−
−
−
−

+
+
+
+
NA

−

NA
−
+
−
−
NA

+
+
+
NA
NA

p.
(Gln326Alafs*5)
hemizygous
de novo

+

−

−

+

−

+

−

NA
−

+
−
−
−
−
−
−

+
+
+
NA
NA

p.(Arg458*)

−

+
−
+
−
−
+

+
+
+
+
mild (to
moderate)

heterozygous
de novo

+

−

−

−

+

+

−

−
−

+
−
+
−
−
−
−

+
+
+
+
Borderline
intellectual
functioning

(100%)
(100%)
(96%)
(94%)

6/24 (25%)

10/20 (50%)
4/23 (17%)
21/25 (84%)
7/23 (30%)
5/25 (20%)
6/23 (26%)

25/25
25/25
24/25
15/16

−

−

−

−

+

+

−

+
−

+
−
+
−
−
−
−

+
+
+
NA
NA

(100%)
(100%)
(100%)
(100%)

No data available
1/12 (8%)
12/12 (100%)
9/12 (75%)
No data available
No data
availablec
No data available

12/12
12/12
12/12
11/11

−

−

+

−

−

−

+

−
−

−
−
+
−
−
−
+

+
+
+
+
NA

hemizygous
de novo

p.(Leu197*)

c.590_593del

male

2y 9m

14

(100%)
(100%)
(97%)
(96%)

6/24 (25%)

10/20 (50%)
5/35 (14%)
33/37 (89%)
16/35 (46%)
5/25 (20%)
6/23 (26%)

37/37
37/37
36/37
26/27

Combined (n=37)

p.
(Leu457Pro)
hemizygous
de novo

c.1370T>C

male

6y 3m

13

Basilicata et al14
(n=12)b

hemizygous
de novo

p.(Met381Argfs*30)

c.1125_1141dup17

male

7y 3m

12

Our cohort
(n=25)a

hemizygous
maternal
mosaicism

c.13821G>A
p.?

male

4y 2m

11

c.1372C>T

17y 2m
female

25

p.
(Gln369*)
hemizygous
de novo

c.1105C>T

male

3y 1m

10

c.973_974del

2y 5m
male

24

+
+
+
NA
NA

p.
(Gln305*)
hemizygous
de novo

c.913C>T

male

3y 1m

9

Table 1 a: Clinical features of individuals 1-14. b: Clinical features of individuals 15-25 and previously published individuals with variants in MSL3.
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Abbreviations: DD = developmental delay; ID = intellectual disability; NA = not available; ASD = autism spectrum disorder; MRI = magnetic resonance imaging
a
Counts for clinical features are given only for those where the respective information was available, therefore the total count can be lower than the total number of individuals
b
Two individuals with deletions spanning more genes than MSL3, one individual with an inherited inversion as well as one individual (reported as P4) who was included in this study as individual 13 were excluded.
c
Three individuals were reported to have an ataxic and broad-based gait.
d
One individual was reported to have retinal abnormalities.
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Most individuals ambulated prior to age of 3 years with the
exception of one individual who did not walk until the age of
4 years. Three individuals (ages: 14 months, 15 months,
33 months) were still non-ambulatory at the time of last
follow-up. Gait abnormalities were present in eight individuals. One individual (individual 17) developed progressive
gait disturbance due to ataxia by the age of 13 years and was
non-ambulatory by the age of 15 years. No other individual
was reported to have lost ambulation.
Receptive language skills seemed to be better developed
than expressive language; however, these observations were
not based on standardized testing. Ten of 25 (40%)
individuals were nonverbal at the time of data collection
(ages: 14 months, 15 months, 29 months, 33 months, 3 years,
3 years, 4 years, 8 years, 16 years, 19 years).
None of the participants showed signs of developmental
regression except for two individuals. Individual 18 displayed
two episodes of developmental regression in his verbal and
cognitive abilities at ages 13 and 18 years from which he
recovered only partially. Neither of these episodes was
associated with a documented triggering event. Individual
17 had regression of his motor skills with progressive gait
disturbance and became nonambulatory. Ten of 20 (50%)
individuals had a diagnosis of autism spectrum disorder
(ASD). Other behavioral abnormalities included attention
deficit–hyperactivity disorder (ADHD) (n = 4), aggressive
behavior (n = 2), anxiety (n = 4), obsessive–compulsive disorder (n = 2), and self-injurious behavior (n = 2). Three
individuals, however, were described as very friendly and
sociable.
Four of 23 (17%) individuals had a history of seizure(s).
Seizures were well controlled with antiepileptic treatment in
all cases. Individual 17, who experienced a single seizure in
infancy, later stopped antiepileptic drugs and has been
seizure-free since then.
MRI findings

To gain further insight into brain MRI abnormalities, relevant
images or whole MRI data sets of eight affected individuals
were evaluated by the same pediatric neuroradiologist
(individuals 1, 2, 3, 11, 15, 16, 17, and 18). Image analysis
revealed hypoplasia of the inferior part of the cerebellar
vermis as a consistent feature in the individuals investigated
(Fig. 2). Variable dilatation at the trigone of the lateral
ventricles was also noted (Fig. S1). In addition, a spectrum of
variable central nervous system (CNS) findings was reported
including nonspecific white matter abnormalities (five
individuals) and moderate widening of external cerebrospinal
fluid spaces (two individuals). Follow-up MRIs were available
for two individuals (2 and 17). In these cases, cerebellar
abnormalities were nonprogressive (Fig. S2).
Additional findings

Macrocephaly (occipital frontal circumference [OFC] > 97th
percentile) (including relative macrocephaly) was present in 3/
14 (21%) individuals at birth, while at the time of the last
387
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Fig. 1 Phenotypic characteristics of males and females with X-linked, MSL3-associated disorder. (a) Facial gestalt of individuals with causative
variants in MSL3 showing dysmorphic features with broad nasal bridge, ear abnormalities (low set and/or posteriorly rotated ears, preauricular tags,
overfolded helices), and coarse facial features in older individuals being the most common characteristics. (b) Using Face2Gene, a composite image based on
the frontal facial images of previously published and newly diagnosed cases with MSL3-associated disorder was created. The mask of the healthy controls
was generated by an age-, sex-, and ethnicity-matched control group. The composite image of individuals with MSL3 variants visualizes dysmorphic and
distinguishing facial features (round face, coarse facial features, broad nasal bridge, puffy eyes, hypertelorism, downslanting palpebral fissures, downturned
corners of the mouth). The aggregated binary comparison (AUC area under the curve, ROC receiver operating characteristic) demonstrates a significant
difference between the two cohorts (p < 0.005). (c) Back-to-back chart visualizes the frequency (in percent) of respective clinical features present in females
(gray bars, n = 10) and males (blue bars, n = 15). The distribution of no feature was significantly different between the respective subgroups (Fisher’s
exact test).
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heterogeneous (12/22; 55%). Eight of 23 (35%) individuals had
conductive and/or sensorineural hearing loss (uni- or bilateral).
Individual 6, who had moderate to severe bilateral sensorineural deafness, also harbored a pathogenic homozygous
STRC gene deletion as an additional genetic finding and was
diagnosed with deafness, autosomal recessive 16 (MIM
603720). We considered it more likely that the pathogenic
variant in STRC primarily contributed to the hearing
impairment in this individual. Skeletal features (e.g., pes
planus, plagiocephaly, pectus carinatum) were evident in 17/
24 (71%) individuals. Abnormalities of the fingers, such as
clinodactyly, tapered and slender fingers, which were observed
in several individuals, are depicted in Fig. S3. A detailed
description of additional findings is provided in the Supplementary case reports and Table S1.
Facial appearance

Fig. 2 Brain magnetic resonance image (MRI) findings in individuals
with pathogenic variants in MSL3. (a) Brain MRI image (T1-weighted
sagittal view) of a healthy individual at the age of 13 years. The white arrow
indicates the inferior part of the cerebellar vermis. (b–i) Brain MRI images
(sagittal views) of individuals with variants in MSL3 (T1-weighted sequences; [f, g] are contrast enhanced sequences). (b) Individual 17 (age 13
years). (c) Individual 15 (age 7 years). (d) Individual 16 (age 5 years). (e)
Individual 11 (age 24 months). (f) Individual 18 (age 18 years). (g) Individual
3 (age 14 months). (h) Individual 1 (age 12 months). (i) Individual 2 (age
20 months). In all individuals with pathogenic variants in MSL3 variable
hypoplasia (or atrophy) of the inferior part of the cerebellar vermis was
observed (white arrows; please compare with normal findings in [a]).

follow-up macrocephaly was seen in 11/21 (52%) individuals
indicating secondary macrocephaly. Birth length was within
normal limits (3rd–97th percentile) in 19/19 (100%) individuals and 4/23 (17%) individuals subsequently developed short
stature (<3rd percentile). Polyhydramnios was evident in 4/18
(22%) pregnancies. A heterogeneous spectrum of gastrointestinal problems, mainly constipation and gastroesophageal reflux
disease, was found in 18/23 (78%) individuals. Five of 23 (22%)
individuals were reported to have urinary symptoms: two
individuals had urinary retention needing catheterization, one
individual had bilateral hydroceles at birth, and two had
hydronephrosis and pyeloureteral junction stenosis, respectively. Respiratory symptoms were observed in 8/21 (38%)
individuals and 4/23 (17%) individuals had abnormalities of the
cardiovascular system. Vision abnormalities were common but
GENETICS in MEDICINE | Volume 23 | Number 2 | February 2021

Dysmorphic facial features were reported in the majority
(n = 23/24 [96%]). Figure 1a displays the facial appearance of
18 individuals for whom facial pictures were available.
Dysmorphic features were relatively mild, especially at a
young age, but commonly shared features were round face,
broad nasal bridge, epicanthal folds, hypertelorism, prominent forehead, and coarse facial features. Additional features
included arched brows, high nasal bridges, abnormal dentition, overbites, narrow palates, and micrognathia. An
abnormal shape or position of the outer ear encompassing
low set and/or posteriorly rotated ears, preauricular tags, and
overfolded helices was present in 14/22 (64%) individuals.
We used Face2Gene RESEARCH application to perform
computer-based facial analyses of 30 individuals with MSL3
variants (12 individuals from Basilicata et al.,14 18 individuals
from this study). The binary comparison between individuals
with MSL3 variants and unaffected controls (age, sex, and
ethnicity matched) yielded an average AUC of 0.976
expressing a significant difference between these two cohorts
(p < 0.005) (Fig. 1b). The aggregated composite facial image/
mask depicts a distinct facial gestalt (round face, coarse facial
features, broad nasal bridge, puffy eyes, hypertelorism,
downslanting palpebral fissures, downturned corners of the
mouth) (Fig. 1b).
Phenotypic differences between females and males

We further evaluated if specific clinical characteristics
significantly (Fisher’s exact test) appear more often in females
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versus males (Table S4). No significant difference regarding
the frequency of clinical features was found between the two
groups. Figure 1c visualizes the comparison of the clinical
features between females and males.
Phenotypic differences between individuals with missense
variants/in-frame deletions and individuals with loss-offunction variants

We further evaluated if specific clinical characteristics
significantly (Fisher’s exact test) appeared more often in
individuals with loss-of-function variants versus individuals
with missense variants/in-frame deletions (Table S4). No
significant difference regarding the frequency of clinical
features was found between the two groups. Figure S4
visualizes the comparison of the clinical features between
both groups.
Variants in affected individuals

We identified heterozygous and hemizygous variants in MSL3
(NM_078629.4) in 25 individuals from 25 independent
families and observed a spectrum of variant types with lossof-function variants being the predominant variant type (n =
21/25). These comprised ten nonsense variants, six frameshift
variants, four splice site variants, and one multi-exon deletion.
In two canonical splice site variants, exon skipping or the use
of a cryptic splice site would disrupt the reading frame. The
variant c.1382–1G>A is predicted to result in an in-frame
product with use of a cryptic splice site (p.[Val461_Pro464del]).19 The splice variant c.1466+1G>A is predicted to lead
to exon skipping with the introduction of a premature
translation termination codon in the last exon (p.[Val461Glyfs*3]) and would most likely not undergo NMD.23,24 The
multi-exon deletion comprises exons 6–8 and is predicted to
result in the disruption of the reading frame (out-of-frame
deletion) as well. All other truncating variants occurred before
the last exon of MSL3 and were predicted to undergo
NMD.23,24 Furthermore, three missense variants as well as
one in-frame deletion were detected that all affected highly
conserved amino acids in the MRG domain. All detected
variants were absent from gnomAD.25 All variants were
classified as likely pathogenic or pathogenic, respectively,
accordingly to the ACMG criteria (Table S2).16
To date, three recurrent variants have been observed: the
variant c.590_593del, p.(Leu197*) was found in two unrelated
individuals from this study (individuals 14 and 20), and the
variants c.1125_1141dup17, p.(Met381Argfs*30) and
c.1372C>T, p.(Arg458*), which were identified in individuals
12 and 25, respectively, were previously reported.14 All
variants were located within the last eight exons (exon
6–13) of MSL3 (NM_078629.4), encoding the MRG domain,
whereas no variants were detected within the first six exons.
Figure 3a visualizes the type and distribution of the variants
described in this study. We furthermore aggregated all so-far
reported causative variants14,26 in MSL3 confirming that
pathogenic variants in MSL3 cluster in the exons encoding the
MRG domain. Figure 3b illustrates the distribution of the
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respective variants. Table S3 summarizes all previously
published variants as well as variants from this study (n = 41).
Parental DNA samples were available for 22 individuals.
Variants were proven to be de novo in 21 of those individuals.
In the healthy mother of individual 11, segregation study
(Sanger sequencing) suggested the variant as low-level mosaic
in blood cells. The variant load of approximately 8% was
estimated using droplet digital polymerase chain reaction
(ddPCR). No respective parental DNA samples were available
for individuals 6, 8, and 20; however, unremarkable family
histories in combination with the finding of pathogenic
variants in those cases suggested likely de novo origins as well.
Overall, we did not identify familial cases.
Molecular modeling reveals common underlying
mechanism

We investigated the 3D pattern of genetic variants on the
encoded protein of the MRG domain. The MRG domain is
predicted to make a bipartite fold where the N- and Cterminal regions intertwine. The substitutions p.(Leu457Pro)
and p.(Arg458Leu), the in-frame deletion p.(Gln454del), as
well as the two splice variants with the predicted consequences p.(Val461_Pro464del) and p.(Val461Glyfs*3) that
presumably escape NMD all occur in the middle of this region
(Fig. 4). These alterations will, most likely, destabilize the fold,
which is necessary for binding to MSL1. The folding energy
(ΔΔGfold) is highly destabilizing for missense variants p.
(Leu457Pro) (5.36 kcal/mol) and p.Arg458Leu (4.02 kcal/
mol), while it is neutral for the variant p.(Asn437Thr)
(−0.23 kcal/mol) in the monomer. The p.(Asn437Thr) variant
is present at the interface of the complex, possibly interfering
with the complex formation.

DISCUSSION
Here, we present 25 individuals (15 male, 10 female) with
disease-causing hemizygous or heterozygous variants in
MSL3, which is the largest cohort of individuals with Xlinked, MSL3-related disorder to date. With the exception of
one individual whose phenotypically normal mother had
germline mosaicism, all cases were either proven (n = 21) or
presumed to be de novo based on family history (n = 3).
Our cohort allowed a more comprehensive definition of Xlinked, MSL3-related disorder as a syndromic condition
affecting females and males equally, with varying degrees of
ID (mild to severe) and DD as the most consistent features.
ASD, found in 50% of all individuals, emerged as a new
feature of X-linked, MSL3-related disorder. Variable neurological findings were common and comprised muscular
hypotonia, upper and lower limb spasticity, abnormal movements (dystonia, ataxia, hypokinesia), and cerebellar vermis
hypoplasia as a consistent MRI finding. Data for longitudinal
MRI studies were only available for two individuals (Fig. S2)
and we can therefore not completely exclude the possibility
that the cerebellar vermis volume loss is progressive
(atrophy). Interestingly, the cerebellar abnormalities were
only identified during reanalysis for several cases and
Volume 23 | Number 2 | February 2021
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Key

c.1319dup, p.(Gly441Argfs*2)
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Fig. 3 Variant type and exon distribution of variants in MSL3 (NM_078629.4). (a, b) Gray boxes illustrate the coding sequence, smaller gray boxes
illustrate untranslated regions (UTRs). The predominant MSL3 transcript NM_078629 (ENST00000312196) and the shorter transcript NM_006800
(ENST00000380693) are shown with numbered exons. Variants identified in this study are depicted above the dotted line (a) and previously reported
variants are presented below (b). The color of the circle represents the corresponding variant type (see key). Overall, the majority of variants are predicted
loss-of-function variants. Three recurrent variants (depicted with stars) were observed. Notably, all newly and previously reported variants (excluding
deletions spanning more genes than MSL3) are confined to the last eight exons (exons 6–13) of MSL3 (NM_078629). No variants affecting only the first five
exons of MSL3 (NM_078629) were identified. (c) Schematic representation of MSL3 protein domains. The chromo domain (CD) (amino acid position 32–90)
is depicted in brown and the MRG domain (amino acid position 168–517) is depicted in green. The shorter transcript NM_006800 corresponds only to the
MRG domain.

comparison with other individuals with MLS3 variants,
highlighting the importance of systematic image analysis in
rare neurological disorders.
A high prevalence of features affecting other organ systems
was encountered, some of which occurred more frequently
than previously reported in the existing literature. Gastrointestinal problems (constipation, gastroesophageal reflux,
and vomiting) as well as disorders of the genitourinary system
were commonly found. Hearing impairment, namely sensorineural and/or conductive hearing loss, macrocephaly, as well
as a variety of visual abnormalities were observed as new
significant features. Polyhydramnios also emerged as a newly
recognized prenatal feature in MSL3-related disorder.
Facial dysmorphism, which appeared rather subtle in the
younger individuals, was described in the majority of
individuals and included several consistent facial features.
Computational facial analysis technology was able to
accurately discriminate between affected individuals and
healthy controls, indicating that affected individuals have a
recognizable facial gestalt that might help to diagnose affected
individuals early using “next-generation phenotyping” or to
guide diagnosis in case of inconclusive genetic results.27
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Among 25 disease-causing variants identified in this cohort,
22 variants were novel. Using ACMG criteria, all variants
were classified as likely pathogenic or pathogenic (Table S2).
Besides considerably expanding the list of likely pathogenic
and pathogenic variants in MSL3, we illustrate a variety of
variant types to be associated with X-linked, MSL3-related
disorder, with loss-of-function variants accounting for
the majority (n = 21/25). Loss-of-function variants and
missense variants were found equally in affected males and
females. Prior to this study, only one individual harboring a
disease-causing missense variant—previously referred to as
p.(Leu308Pro) and listed here as p.(Leu457Pro)—in MSL3
had been reported.14 Of note, this individual was also
included in this study (as individual 13) after obtaining
additional follow-up data. Herein, we describe two additional
missense variants (p.[Asn437Thr] and p.[Arg458Leu]) as well
as one in-frame deletion (p.[Gln454del]) confirming that
missense variants and in-frame deletions are part of the
genotypic spectrum of MSL3-related disorder. Whereas the
missense variant p.(Asn437Thr) is predicted to impair
complex formation with MSL1 the substitutions p.(Leu457Pro), and p.(Arg458Leu) as well as the in-frame deletion
391
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Fig. 4 Overview of the position of case variants on the MSL3–MSL1 tetrameric complex. (a) MSL3–MSL1 tetrameric complex with the N-terminal
and C-terminal MRG regions from one monomer highlighted in pale green and salmon. The sites of missense variants are marked by red spheres.
p.(Asn437Thr) is the first amino acid in the disordered loop and is present at the interface of the tetramer. p.(Leu457Pro) and p.(Arg458Leu) are located
within the bipartite fold region. (b) The environment around the case variants is shown in sticks. The Arg458 residue interacts with Asp187 and Glu278 of
the N-terminal region of the MRG domain. (c) The structure is highlighted based on hydrophobicity which ranges from red (hydrophobic) to white
(hydrophilic). It is visually evident that one side of this region is highly hydrophobic and includes Leu457, while the other side is hydrophilic and includes
Arg458 and Gln454. (d) Variant Asn437Thr is marked by a red sphere, present at the monomer–monomer interface. (e, f) The amino acids removed by
splice variants are colored in black and affect the same region as missense variants.

p.(Gln454del) all affect highly conserved amino acids
disrupting the bipartite fold region of the MRG domain.12,28
The lack of clinical differences between individuals with lossof-function and missense variants in our cohort (Fig. S5,
Table S4) points toward a loss of function as the mutational
mechanism. However, this analysis has a low power and
larger studies might identify subtle differences between these
groups.
All currently reported causative variants (excluding multigene deletions) (n = 41) were confined to the last eight exons
(exon 6–13) of MSL3 with exon 9 (n = 14) and exon 11 (n =
11) being most frequently affected whereas no pathogenic
variants were observed in the first exons in individuals with
MSL3-associated disease (Table S3).14,26 The latter finding
might indicate that translation of the shorter transcript
NM_006800 (ENST00000380693), which lacks the CD and is
only comprised of the MRG domain responsible for
interaction with MSL1, can rescue gene function (functional
MSL complex) even in the presence of variants in the first
exons. These findings suggest that the N-terminal CD of
MSL3 is either redundant or that a mutant CD is associated
with traits different than those seen in Basilicata–Akhtar
syndrome. One case (nsv1075719) with a deletion comprising
the first exon is listed in the Database of Genomic Variants
(DGV) and an additional case with a heterozygous frameshift
variant p.Lys34ArgfsTer20 in the first exon in the longer
transcript NM_078629 is listed in gnomAD, compatible with
392

the hypothesis that the CD is redundant.25,29 However, it
should be noted that the variant listed in gnomAD has low
coverage and poor base quality. Another explanation for the
observed pattern is that loss-of-function variants in the first
five exons are not viable and that loss-of-function variants in
the eight C-terminal exons escape NMD and result in the
translation of a truncated protein with residual function.
However, the full gene deletion argues against this
possibility.25,29
It should be noted that our cohort contains one individual
(individual 11) with parental germline mosaicism (variant
allele fraction of 8% in a phenotypically normal mother). This
represents the first genetically confirmed case of parental
germline mosaicism in the context of X-linked, MSL3-related
disorder.
MSL3 was recently found to escape X-chromosome
inactivation (XCI).30 X-linked genes that largely escape from
XCI (escapees) have been linked to genetic disorders that
affect both female and male individuals, however, with sexspecific differences.30–34 We therefore conducted a comparative analysis between females and males to evaluate possible
sex-specific differences (Table S4). Our cohort included 15
males and 10 females with disease-causing variants in MSL3
and we did not identify significant differences regarding
the frequency of clinical features between the two groups.
The absence of obvious differences between males and
females is so far unexplained and future studies are
Volume 23 | Number 2 | February 2021
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required to elucidate the precise molecular basis behind this
phenomenon.
Even though specific treatment is not available to date, we
observed a large number of disease-associated complications,
which can be managed symptomatically. Based on the clinical
phenotypic delineation in this MSL3-associated disorder
cohort, we propose the following clinical management and
follow-up recommendations. Following diagnosis, affected
individuals should be referred to the following: (1) a
(pediatric) ophthalmologist as impairment of the visual
system was frequent and early therapy may be required to
avoid amblyopia; (2) a (pediatric) otolaryngologist as hearing
impairment should be treated early with hearing aids or
cochlear implants; (3) gastroenterological evaluation for
feeding problems and gastroesophageal reflux disease; (4)
nephrology assessment including kidney ultrasound is
recommended to detect structural abnormalities early that
may predispose to urinary tract infections and/or subsequent
renal damage; prophylactic treatment and follow-up by a
renal specialist may be indicated; (5) evaluation of the skeletal
system for malformations, which may require orthopedic
management; and (6) regular neurodevelopmental and
neurological follow-up because developmental delay, behavioral abnormalities, movement disorders, and seizures
contributed most to disease burden.
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